Reported figures and Equlion model projections for the next 5 years.
Metric
2025 (actual)
2026
2027
2028
2029
2030
Trend
ROE
33.08%
22.94%
20%
18.07%
16.39%
14.59%
ROA
16.81%
19.37%
17.23%
15.8%
14.5%
13.04%
Gross Margin
58.79%
58.79%
58.79%
58.79%
58.79%
58.79%
Sector average
16.85%
17.71%
17.71%
17.71%
17.71%
17.71%
Net Margin
Amounts in SEK (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2025. Projections are model estimates, not investment advice.
Want the full financial forecast report for Xbrane Biopharma AB (publ)? It covers the balance sheet, income statement and Equlion model projections.
83.49%
78.59%
75.57%
71%
67.66%
65.91%
Total Assets
SEK 671,623.00K
SEK 828,083.70K
SEK 992,781.61K
SEK 1,175,812.93K
SEK 1,371,338.14K
SEK 1,569,400.96K
Sector average
SEK 2,857,190.78K
SEK 2,900,240.60K
SEK 3,045,009.79K
SEK 3,280,286.42K
SEK 3,536,407.14K
SEK 3,762,908.71K
Net Income
SEK 127,242.00K
SEK 145,253.42K
SEK 156,847.42K
SEK 171,355.25K
SEK 184,627.62K
SEK 191,802.71K
Sector average
-SEK 2,851.32K
-SEK 22,027.28K
-SEK 904.69K
-SEK 7,253.84K
-SEK 3,858.45K
-SEK 1,547.00K
Valuation
SEK 210,174.55K
SEK 214,198.96K
SEK 218,240.13K
SEK 222,246.47K
SEK 226,253.83K
SEK 230,400.51K
Sector average
SEK 3,960,502.41K
SEK 5,151,301.60K
SEK 5,189,236.02K
SEK 5,317,343.69K
SEK 5,514,329.75K
SEK 5,636,782.17K
Stock Price
SEK 10.20
SEK 10.40
SEK 10.59
SEK 10.79
SEK 10.98
SEK 11.18
Sector average
SEK 57.22
SEK 48.04
SEK 48.69
SEK 50.45
SEK 52.13
SEK 53.41
Xbrane Biopharma AB (publ) (XBRANE.ST) Financial Forecast | Equlion
